Healthcare RCM Platforms Draw a PE Investment Wave in 2026.

Private equity's move into healthcare revenue cycle management (RCM) platforms accelerated sharply in 2026, with Carlyle, Longshore Capital Partners, and Serent Capital each backing RCM or price-transparency-adjacent assets within the same week ^[1]. The proximate driver is regulatory, not cyclical: federal price-transparency requirements have converted billing and claims infrastructure that health systems once treated as a cost center into a compliance-critical software category with recurring-revenue economics ^[1]. For mid-market sponsors, the immediate implication is a narrowing window — entry multiples on regional RCM platforms are moving before most origination teams have finished mapping the category.

Revenue cycle management is the set of administrative and clinical-adjacent functions — patient registration, eligibility verification, coding, claims submission, denials management, and collections — that convert a healthcare encounter into cash on a provider's balance sheet.

Federal price-transparency rules turned RCM into a compliance category, not a back-office line item.

SEVA's move into the healthcare price-transparency sector this year was explicitly framed as a response to federal rules, not a bet on underlying healthcare demand growth ^[1]. That distinction changes how sponsors should underwrite the category. Demand-driven software businesses live and die on customer acquisition; compliance-driven software businesses live and die on switching costs, because a provider that fails to comply faces regulatory exposure rather than merely a worse product experience.

RCM platforms increasingly sit at the intersection of both dynamics. Providers need them to get paid, and they increasingly need them to satisfy disclosure and billing-transparency mandates that did not exist a decade ago ^[1]. That combination — mandatory adoption layered on top of recurring transactional revenue — is precisely the profile that turns a services business into a multiple-expanding platform, and it is why sponsors that historically avoided healthcare services on the grounds that reimbursement risk is unpredictable are now underwriting RCM as a software category instead.

The obvious objection is that federal rules can be delayed, narrowed, or reversed by a future administration, and that a thesis built on regulatory tailwind is inherently fragile. That risk is real, and it is why diligence on RCM assets increasingly separates "compliance-incidental" revenue — contract value that exists because of a specific disclosure mandate — from "transaction-core" revenue tied to the basic mechanics of claims submission and collections that would persist under any regulatory regime. A platform overexposed to the former is a bet on Washington; a platform anchored in the latter is a bet on healthcare billing complexity, which has only moved in one direction over the past two decades.

Carlyle, Longshore, and Serent are chasing the same mechanism through different deal shapes.

The three firms represent distinct check sizes, hold periods, and playbooks, yet all three converged on RCM-adjacent assets within a single reporting week ^[1]. Carlyle typically enters at platform scale with buy-and-build capital already committed; Longshore Capital Partners and Serent Capital more often underwrite growth-equity or lower-mid-market platforms with runway to build out add-on infrastructure themselves. Convergence across that spectrum, inside a category that was a niche services line five years ago, is the pattern worth tracking — not the specific terms of any one transaction.

Skeptics will point out that three deals in a week is a small sample, and that headline convergence often reflects reporting coincidence rather than a structural shift. That objection is fair on its own, but it misreads what the convergence indicates. When sponsors with different mandates, different check sizes, and different hold-period assumptions independently arrive at the same category in the same window, the more likely explanation is that the category had already been re-priced in private conversations that predate the public announcements — the deals close together because the underwriting logic became obvious to multiple firms at roughly the same time, not because of coordination ^[1].

Consider a stylized version of the assets these firms are chasing: a regional RCM vendor processing claims for forty mid-sized physician groups, generating $18 million in revenue at a 22 percent EBITDA margin, with 85 percent of revenue under multi-year contract. Two years ago, an asset with that profile likely traded as a services business at 6-7x EBITDA. Today, if the vendor can demonstrate that a meaningful share of its contract value is tied to price-transparency compliance work rather than discretionary billing support, the same asset is increasingly underwritten closer to 9-10x — not because the underlying cash flow changed, but because the durability assumption attached to that cash flow did. That repricing, replicated across a category with thousands of similarly sized regional vendors, is the actual mechanism behind the convergence.

Shareholder activism is adding a second pressure vector on health systems to outsource billing.

2025 was the most prolific year on record for shareholder activism, with more than 255 campaigns launched globally and US activity up 28 percent year over year ^[2]. Japan set its own record at 56 new campaigns, underscoring that the pressure is not confined to US public markets ^[2]. Activist investing has also become structurally more accessible — 29 percent of 2025 campaigns came from newer or smaller activist entrants — which means funds with narrower theses are now capable of launching credible campaigns against mid-cap healthcare operators that would have been insulated from that kind of scrutiny five years ago ^[2].

The 2026 proxy season complicates a simple "more activism, more pressure" narrative, and the nuance matters for how sponsors should read the signal. Overall proposal filings continued to decline and the raw number of activism campaigns fell sharply from the 2025 peak, even as say-on-pay support improved ^[3]. Boards, meanwhile, faced heightened legal complexity, more fragmented voting influence, and a regulatory environment still in flux ^[3]. Read together, the picture is not one of activism receding — it is one of activism becoming more targeted: fewer broad campaigns, but the ones that land carry narrower, harder-to-deflect asks on cost structure, precisely the kind of asks a board can answer by outsourcing non-core billing operations.

That is the mechanism connecting activism to RCM deal flow, and it has little to do with healthcare policy specifically. A management team facing a proxy fight, or the credible threat of one, needs a visible near-term margin improvement it can point to on the next earnings call, and outsourcing revenue cycle operations to a specialist vendor is one of the few operational changes that shows measurable EBITDA impact within two or three quarters — faster than a facility consolidation, a payer renegotiation, or a clinical staffing change, all of which carry longer timelines and more execution risk. Boards under that kind of scrutiny are, in effect, subsidizing demand for RCM platforms whether or not that was any activist's stated intent.

The RCM thesis mirrors a broader pattern in compliance-driven vertical software.

Long Ridge Equity Partners' investment in MarketSphere, an unclaimed-property compliance specialist founded in 2002 that helps enterprise and mid-market organizations manage compliance across US and Canadian jurisdictions, is the closest available comp outside healthcare ^[4]. The parallel is structural, not incidental: both categories combine a mandatory compliance obligation, high switching costs once a client's data lives inside the platform, and a fragmented incumbent base still running on manual or semi-manual processes.

Three traits recur across the compliance-driven vertical software category that sponsors are now applying almost interchangeably to RCM, tax advisory, and unclaimed-property targets:

• Mandatory adoption. The client cannot simply decide not to comply; the only variable is which vendor handles it.
• High data-migration cost. Once client records, claims history, or property records live inside a platform, switching vendors requires a migration project most clients will defer indefinitely.
• Fragmented, founder-owned supply. Incumbents are typically regional or specialty-specific operators who built durable client relationships long before a national platform existed to consolidate them.

Sponsors who have already underwritten compliance-adjacent vertical software — tax advisory roll-ups, unclaimed-property specialists, regulatory reporting platforms — are applying the same diligence framework to RCM: recurring contract value, regulatory tailwind durability, and the percentage of revenue that survives a change in ownership. That transferability of diligence frameworks is itself accelerating capital flow into RCM, because sponsors do not need to build a new underwriting model from scratch; they are reusing one already stress-tested in an adjacent category ^[4]. Related reading: rollup economics covers how consolidation math plays out once a platform starts adding on.

AI underwriting is becoming a differentiator inside RCM platforms, not just a pitch-deck slide.

Ode, a PE-backed enterprise AI transformation company built with Anthropic, acquired AI services firm Casper Studios this year — a concrete example of a platform acquiring AI-enablement capability through M&A rather than building it internally ^[5]. The same logic applies inside RCM. Denial prediction, claims scrubbing, and prior-authorization automation are exactly the workflows where a rules-based legacy system underperforms a properly trained model, and sponsors are now asking a more specific diligence question than they were eighteen months ago: is the target's automation layer defensible intellectual property, or a thin wrapper around a third-party vendor that any competitor can license tomorrow.

The economics of that distinction are large enough to move a valuation. Consider an illustrative platform processing two million claims a year at an average claim value of $350, with an 8 percent initial denial rate. A one-percentage-point reduction in denials — a realistic improvement from better predictive scrubbing before submission — recovers roughly $700,000 in claims value annually before accounting for rework labor saved on the denials-management side. Scale that improvement across a book of forty client health systems and the aggregate EBITDA impact of a defensible automation layer becomes large enough to justify a materially different entry multiple than a platform offering the same service with off-the-shelf tooling.

That gap increasingly separates platform-grade RCM assets from services businesses masquerading as software. A billing shop with strong client relationships but no proprietary automation is a services roll-up candidate priced on EBITDA multiples; an RCM platform with a defensible AI layer and measurable denial-rate improvement is a software asset priced on ARR-adjacent multiples. The diligence question that determines which bucket a target falls into — proprietary model versus licensed wrapper — is now one of the highest-leverage questions in a healthcare services thesis, and it is frequently the question sellers are least prepared to answer with specificity ^[5].

Leadership continuity at platform-focused PE firms signals sustained deployment, not a pause.

Charlesbank's transition to co-managing partners Brandon White and Sandor Hau, with Michael Choe — who led the firm for 12 years as president and then CEO — moving to managing partner emeritus, is one data point in a broader pattern of established platform-investing firms refreshing leadership while preserving strategic continuity ^[6]. Succession structured this way, rather than as an abrupt changing of the guard, typically preserves existing deal pipelines and diligence relationships rather than disrupting them.

For mid-market sponsors watching healthcare services specifically, the relevant takeaway is indirect but real: firms with active healthcare or vertical-software mandates that are refreshing leadership without pausing deployment are signaling continued capital availability into 2026 and 2027, not a retreat from the category. Continuity at the top of platform-investing firms tends to matter more for a category like RCM, where sourcing relationships with founder-owned vendors take years to build, than it does for firms running shorter, more transactional strategies.

What this means for mid-market sourcing in 2026.

The RCM opportunity is not concentrated in a handful of national platforms — it is distributed across thousands of regional billing shops, specialty-specific claims processors, and price-transparency compliance vendors that have not yet been mapped by a sponsor's origination team. Identifying which of those founder-owned vendors are quietly signaling a sale before they reach a banked auction is the sourcing problem our sourcing engine exists to solve.

A simple framework — call it the RCM Readiness Score — helps triage targets before committing diligence capacity:

• Payer mix concentration. Heavy dependence on one or two payers or specialties raises churn risk regardless of software quality.
• Regulatory tailwind exposure. Does the target's core offering map directly to a federal price-transparency or disclosure requirement, or is compliance incidental to the product ^[1]?
• Automation defensibility. Is denial prediction or claims automation proprietary, or licensed from a vendor any competitor can also access ^[5]?
• Revenue durability under ownership change. What percentage of contracted revenue is tied to the founder's personal relationships versus the platform itself?
• Governance exposure of the client base. Are the target's health-system clients under active activist or proxy pressure to cut costs, which could accelerate or threaten the contract depending on which side of the outsourcing decision the client lands on ^[2][3]?

Applying that score to the stylized $18 million regional vendor described earlier illustrates why sponsors are moving quickly: a target scoring well on regulatory tailwind exposure and automation defensibility, but concentrated in two payers, is not a pass — it is a target where the payer-concentration risk should be priced into the deal structure rather than used to walk away, because the other two factors are increasingly scarce in the category. Sponsors that build this scoring discipline into origination — rather than relying on inbound from bankers running the same handful of auction processes every other fund is bidding on — are the ones most likely to capture RCM assets before the category fully re-prices. Related reading: buying signals covers the operational and financial signals that typically precede a founder's decision to sell.

The deal count is still small enough that no single outcome defines the category. But three independent sponsors converging on the same asset class in one week, layered on top of a record year for activist pressure on healthcare margins and a proxy season that rewarded narrowly scoped cost-cutting asks, is the kind of coincidence that tends to look obvious in hindsight — and expensive to anyone who waited for it to become obvious.

FAQ: Healthcare RCM Platform PE Investment